Pfizer (PFE)

As the pharmaceutical industry enters the heart of its Q4 2025 earnings season this February 2, 2026, a clear divide has emerged between the high-flying giants of the metabolic gold rush and those struggling to navigate the steepest regulatory and patent hurdles in a generation. With major reports from Eli

Novo Nordisk just introduced a GLP-1 pill, but the company makes more than just weight-loss drugs.

UK regulators ruled Sanofi breached industry rules over RSV claims in a newspaper interview, following a complaint from Pfizer about Beyfortus promotion.

Large-cap biopharma offers stable growth and dividends, outperforming the S&P 500 in early 2026. With Gilead up 46% and Pfizer yielding 6%, the sector remains a key volatility hedge following successful U.S. manufacturing negotiations.

Pfizer's stock has risen off its lows, but remains 50% below its 2021 highs.

Last week we saw a plethora of important earnings results and increased market volatility. This wee should be another busy one with a lot of important companies due to report.

Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.

Global pharmaceutical company Pfizer (NYSE:PFE) will be reporting earnings this Tuesday before market open. Here’s what investors should know.

Pfizer has fallen behind the pack when it comes to GLP-1 drugs, but the company is still fighting.

Johnson & Johnson is a picture of stability.

All three can provide you with solid, consistent income.

This genomics stock appears to be at an inflection point.

The business may not be as strong as its performance this year suggests.

If you like dividend stocks, here's a high yielder, a Dividend King, and a turnaround story to consider as January comes to a close.

After a years-long revenue drought, there's a light at the end of the tunnel.

As the final days of January 2026 unfold, the financial world is fixed on the steps of the U.S. Supreme Court. A landmark decision in the consolidated cases of Learning Resources, Inc. v. Trump and Trump v. V.O.S. Selections, Inc. is expected within weeks, representing the most

In a landmark shift for the biotechnology and pharmaceutical industries, the U.S. Food and Drug Administration (FDA) has officially entered what experts call the “Enforcement Era” of artificial intelligence. Following the release of the January 2026 Joint Principles in collaboration with the European Medicines Agency (EMA), the FDA has unveiled a rigorous new regulatory framework [...]

They could perhaps see sustained runs beyond this year.

Pfizer Inc. (PFE) shares are trading higher on Tuesday, as the stock benefits from a price target increase at Cantor Fitzgerald. The firm raised its target to $27 from $24, providing a catalyst for the pharmaceutical giant even as the broader Healthcare sector declined 1.6% during the session.

Aclaris Therapeutics reported early study results showing its ATI-2138 drug drove rapid and lasting hair regrowth, outperforming Pfizer's Litfulo in a severe hair loss mouse model.